{"id":745697,"date":"2018-07-02T05:30:00","date_gmt":"2018-07-02T05:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/"},"modified":"2025-11-07T01:27:11","modified_gmt":"2025-11-07T06:27:11","slug":"merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/","title":{"rendered":"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that new data from the company are scheduled to be<br \/>\n      presented at the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aids2018.org%2F&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=22nd+International+AIDS+Conference&amp;index=1&amp;md5=e83cd13c531b042a278eb094dad9b96d\" rel=\"nofollow\">22<sup>nd<\/sup><br \/>\n      International AIDS Conference<\/a> (AIDS 2018) taking place July 23-27 in<br \/>\n      Amsterdam. Presentations include Week 96 data from the Phase 3<br \/>\n      DRIVE-FORWARD clinical trial for doravirine (DOR) and additional<br \/>\n      analyses for DOR and investigational therapy MK-8591. DOR is a<br \/>\n      non-nucleoside reverse transcriptase inhibitor (NNRTI) under<br \/>\n      investigation as a single tablet for use in combination with other<br \/>\n      antiretroviral (ARV) agents and as a fixed-dose combination with<br \/>\n      lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) for the<br \/>\n      treatment of HIV-1 infection in adult patients with no prior ARV<br \/>\n      treatment history (treatment-na\u00efve). MK-8591 is an investigational<br \/>\n      nucleoside reverse transcriptase translocation inhibitor (NRTTI)<br \/>\n      currently being evaluated in clinical trials for the treatment of HIV<br \/>\n      infection.\n    <\/p>\n<p>\n      \u201cWhile enormous progress has been made in the fight against HIV\/AIDS,<br \/>\n      continued scientific innovation is needed given the unmet need that<br \/>\n      continues to exist in HIV,\u201d said Dr. George Hanna, vice president and<br \/>\n      therapeutic area head of infectious diseases, global clinical<br \/>\n      development, Merck Research Laboratories. \u201cMerck looks forward to<br \/>\n      presenting these new data from our HIV pipeline at AIDS 2018.\u201d\n    <\/p>\n<p>\n      Presentations include a late-breaking poster of the Week 96 data from<br \/>\n      the pivotal Phase 3 DRIVE-FORWARD clinical trial evaluating the safety<br \/>\n      and efficacy of once-daily DOR compared to once-daily ritonavir-boosted<br \/>\n      darunavir (DRV+r), each administered with either emtricitabine\/tenofovir<br \/>\n      disoproxil fumarate (FTC\/TDF) or abacavir\/lamivudine (ABC\/3TC), in<br \/>\n      treatment-na\u00efve adults with HIV-1 infection. In addition, analyses of<br \/>\n      the resistance profiles of DOR and MK-8591 will be presented.\n    <\/p>\n<p>\n      Data to be presented include:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Doravirine Versus Ritonavir-Boosted Darunavir: 96-Week Results of<br \/>\n        the Randomized, Double-Blind, Phase 3 DRIVE-FORWARD Noninferiority<br \/>\n        Trial. Abstract LBPEB017. K. Squires. Late-breaking Poster Exhibition:<br \/>\n        Wednesday, July 25, 12:30-14:30 CET, Poster Exhibition Area, Hall 1<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine<br \/>\n        in Combination with the Novel NRTTI MK-8591. Abstract THPEB068. D.<br \/>\n        Hazuda. Poster Exhibition: Thursday, July 26, 12:30-14:30 CET, Poster<br \/>\n        Exhibition Area, Hall 1<\/i>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Characterization of Doravirine-Selected Resistance Patterns from<br \/>\n        Participants in Treatment-Na\u00efve Phase 3 Clinical Trials. Abstract<br \/>\n        THPDB0101. M. Lai. Poster Discussion: Thursday, July 26, 13:00-14:00<br \/>\n        CET, Emerald Room<\/i>\n      <\/li>\n<\/ul>\n<p>\n      Earlier this year, the U.S. Food and Drug Administration (FDA) accepted<br \/>\n      for review New Drug Applications for DOR and DOR\/3TC\/TDF for the<br \/>\n      treatment of HIV-1 infection in treatment-na\u00efve adults. The FDA has set<br \/>\n      a target action date of October 23, 2018 for both applications.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world&#8217;s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer&#8217;s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=de770bc230b0e34dd063e30b543ebf53\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=81781dd74e806e31fab6376f06a7bd8a\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=7add6a441ad262bdf1ae37925595eb15\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=8cd461c3d2fba8757cd2d0c799c1fc54\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=b643672b0f31efe7964122b4bb57d1ca\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck%2F&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=354992e441afd360f49795fd74ef8dca\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51830881&amp;newsitemid=20180702005315&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=04b657650ef5d43724fb15bde26f3aad\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180702005315r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Carmen        de Gourville, 267-305-4195<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from the company are scheduled to be presented at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27 in Amsterdam. Presentations include Week 96 data from the Phase 3 DRIVE-FORWARD clinical trial for doravirine (DOR) and additional analyses for DOR and investigational therapy MK-8591. DOR is a non-nucleoside reverse transcriptase inhibitor (NNRTI) under investigation as a single tablet for use in combination with other antiretroviral (ARV) agents and as a fixed-dose combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history (treatment-na\u00efve). MK-8591 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) currently being evaluated in clinical trials for the treatment of HIV infection. \u201cWhile enormous progress has been made in<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745697","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from the company are scheduled to be presented at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27 in Amsterdam. Presentations include Week 96 data from the Phase 3 DRIVE-FORWARD clinical trial for doravirine (DOR) and additional analyses for DOR and investigational therapy MK-8591. DOR is a non-nucleoside reverse transcriptase inhibitor (NNRTI) under investigation as a single tablet for use in combination with other antiretroviral (ARV) agents and as a fixed-dose combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history (treatment-na\u00efve). MK-8591 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) currently being evaluated in clinical trials for the treatment of HIV infection. \u201cWhile enormous progress has been made in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\\\/\",\"name\":\"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-07-02T05:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from the company are scheduled to be presented at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27 in Amsterdam. Presentations include Week 96 data from the Phase 3 DRIVE-FORWARD clinical trial for doravirine (DOR) and additional analyses for DOR and investigational therapy MK-8591. DOR is a non-nucleoside reverse transcriptase inhibitor (NNRTI) under investigation as a single tablet for use in combination with other antiretroviral (ARV) agents and as a fixed-dose combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history (treatment-na\u00efve). MK-8591 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) currently being evaluated in clinical trials for the treatment of HIV infection. \u201cWhile enormous progress has been made in","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:11+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/","name":"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-07-02T05:30:00+00:00","dateModified":"2025-11-07T06:27:11+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8bf9eb49-c780-4abc-8176-1c006d40dc30","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745697\/revisions"}],"predecessor-version":[{"id":3675040,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745697\/revisions\/3675040"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745697"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}